The problem is not the expense of the drug but rather the shortage of supply, which would immediately be rectified if other companies were able to produce it,

By then, we'd better have this problem rectified or we'll have a serious problem,

We're not going to hide that PML is a problem with this drug. But we're also not going to hide its strong efficacy profile.

When you put together a prescription drug bill that puts the pharmaceutical and insurance industry first, and the recipients way down at the bottom, of course you're going to get one big mess. And we have it.

We have a drug problem. We have to do something.

There is zero consultation, ... That is not what the founders intended.